Today's Rundown Lilly, Pfizer's phase 3 pain data show mixed efficacy, clear safety issues Mustang flying high as 'bubble boy' gene therapy aces small study BI and Lilly's diabetes drug Jardiance reverses heart failure in animal models [Sponsored] Mitotech: a Dry Eye treatment aimed at mitochondria IBM to wind down Watson's work in AI-based drug discovery: report EuroBiotech Report—GSK cuts, Genfit at the FDA, Kiadis buys CytoSen, Cerevance hire and Acticor FiercePharmaAsia—Indian generics contenders; Chi-Med's HK listing; Qilu Pharma explosion Chutes & Ladders—Gilman buckles in as Arrakis raises $75M, while Wotton takes over at Obsidian Featured Story | | | Friday, April 19, 2019 A phase 3 trial has painted a mixed picture of the safety and efficacy of Eli Lilly and Pfizer’s painkiller tanezumab. Neither dose of the nerve growth factor inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments. |
|
|
Top Stories Friday, April 19, 2019 They’re using the “c” word. Mustang Bio’s stock leapt more than 400% in after-hours trading Wednesday on the news that a gene therapy it licensed from St. Jude Children’s Research Hospital cured eight infants with “bubble boy” syndrome. Friday, April 19, 2019 Mount Sinai researchers showed that in a pig model of heart failure, the diabetes drug Jardiance improved heart function. After two months of treatment, the animals experienced reductions in pulmonary congestion and biomarkers of heart failure. Monday, April 15, 2019 Mitotech – a biotech specializing in targeting mitochondria – is moving into late stage of clinical development in Dry Eye Disease. Thursday, April 18, 2019 IBM is ending sales of its Watson programs aimed at artificial intelligence-based drug discovery and development due to poor financial returns, according to a report from Stat. Thursday, April 18, 2019 In this week's EuroBiotech Report, GSK plans R&D cuts, Genfit gets breakthrough status and Kiadis pens deal to buy CytoSen. Friday, April 19, 2019 A group of Indian generics makers is starting to take the lead in U.S. generics prescriptions; Chi-Med has filed to list on the Hong Kong Stock Exchange; an explosion at a Qilu Pharma subsidiary killed 10 workers and injured 12. Friday, April 19, 2019 Gilman buckles in as Arrakis raises $75 million, while Wotton takes over at Obsidian; ex-GSK immunology chief to lead Kintai Therapeutics; and Insys swaps CEOs as Subsys marketing crackdown continues. Those moves plus more hirings, firings and retirings throughout the industry. Resources Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 